Companies ›Healthcare ›BFRI.O

BFRI.O — NASDAQ Pharmaceuticals

Biofrontera Inc

$1,21

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-27,2 %

ROE

-100,5 %

Net margin

-25,3 %

Debt / equity

0,44

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,80

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Biofrontera Inc is a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT) products for the treatment of skin diseases, primarily actinic keratosis and acne.

Business. Biofrontera Inc (BFRI.O) is a pharmaceutical company operating within the Healthcare sector, specifically focused on Pharmaceuticals & Medical Research. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target6,00

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

6,00

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-100,5 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning BFRI.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to BFRI.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Biofrontera Inc (BFRI.O) is a pharmaceutical company operating within the Healthcare sector, specifically focused on Pharmaceuticals & Medical Research. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals

AI synthesis

GENERATED

### Capital Structure and Liquidity Biofrontera has a current ratio of 1.52, indicating that it has $1.52 in current assets for every $1 of current liabilities. The company's liquidity position is assessed as low, with cash and equivalents amounting to $6.39 million against total liabilities of $18.08 million. The debt-to-equity ratio of 0.44 suggests a relatively conservative capital structure, with long-term debt of $4.59 million compared to total equity of $10.48 million.

### Profitability and Returns The company reported a net loss of $10.54 million for the period, with an operating loss of $11.35 million. Return on equity (ROE) is negative at -100.53%, and return on assets (ROA) is also negative at -36.89%, indicating poor profitability relative to its equity and asset base. These metrics fall significantly below the industry median for profitability in the pharmaceutical sector, which typically sees positive ROE and ROA figures.

### Segments and Geographic Exposure Biofrontera's revenue is concentrated in a single product line, Ameluz, which is used in photodynamic therapy for skin conditions. The company's geographic exposure is primarily in the United States, where Ameluz is marketed and sold. There is no disclosed international revenue, suggesting a high concentration risk in the U.S. market.

### Growth Trajectory The company's revenue for the period was $41.71 million. While this represents a positive figure, the operating and net losses indicate that the company is not yet profitable. Analysts have provided a mean price target of $6.00, with a median of $6.00 and a high of $9.00, suggesting a cautious but not overly optimistic outlook.

### Risk Factors The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow of $13.36 million and free cash flow of $10.40 million suggest ongoing cash burn, which could become a concern if not addressed through additional financing or improved operational performance.

### Recent Events Recent filings and transcripts do not indicate any major events that would significantly impact the company's financial position or strategic direction. The company continues to focus on the commercialization of Ameluz and the expansion of its product pipeline.

Key takeaways

Biofrontera operates in the pharmaceuticals industry with a focus on photodynamic therapy for skin diseases.
The company has a low liquidity position and is currently unprofitable, with negative returns on equity and assets.
Revenue is concentrated in a single product and geographic market, increasing exposure to market-specific risks.
Analysts have a cautiously neutral outlook, with a mean price target of $6.00.
The company has low dilution risk but faces challenges in generating positive cash flow and achieving profitability.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1,21

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$10.5M

Net cashⓘ

$1.8M

Current ratioⓘ

1.5

Debt / equityⓘ

0.4

ROAⓘ

-36.9%

ROEⓘ

-1.0%

Cash conversionⓘ

127.0%

CapEx / revenueⓘ

0.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs BFRI · multiples and returns

JNJ—

Johnson & Johnson

$254,43

622,1B USD

P/E

23,5x

— vs self

Div yield

2,0 %

— vs self

ROE

33,0 %

+133,6 vs self

LLY—

ELI LILLY AND COMPANY

$1 124,04

1,01T USD

P/E

52,0x

— vs self

Div yield

0,5 %

— vs self

ROE

66,2 %

+166,7 vs self

MRK—

MERCK & CO., INC.

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

PFE—

Pfizer Inc

$25,05

143,6B USD

P/E

18,2x

— vs self

Div yield

6,9 %

— vs self

ROE

8,6 %

+109,2 vs self

ABBV—

Abbvie Inc

$245,10

434,8B USD

P/E

110,6x

— vs self

Div yield

2,5 %

— vs self

ROE

-63,5 %

+37,0 vs self

AZN—

AZN.L

$157,59

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BMY—

Bristol-myers Squibb Co

$65,60

134,3B USD

P/E

17,7x

— vs self

Div yield

4,1 %

— vs self

ROE

31,6 %

+132,1 vs self

GSK—

Gsk Plc-spon Adr

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,04

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-04 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,04
Revenue	—no estimate	—no estimate	46,8M USD
Operating income	—no estimate	—no estimate	-424,500 USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution2 analysts

Strong buy0

Buy2

Hold0

Sell0

Strong sell0

12-month price target$6,00 · Median $6,00

Low $3,00High $9,00

Operating income · consensus-424,500 USD

EPS surprise

−2 871,4 %

reported vs consensus · miss

Revenue surprise

−10,8 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$3,00

Mean$6,00

Median$6,00

High$9,00

Spot$1,21

+396.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-27,2 %Bottom quartile

Net Margin-25,3 %Bottom quartile

ROE-100,5 %Bottom quartile

Capex / Rev0,0 %Above P75

D/E0,44Below median

Cash Conv1,27Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 5 036 172 sh4 exercises · 11 grants8 insiders

Luebbert HermannDirector, CEO & Chairman · Restricted Stock Units → Common StockDisposed 137 500exercise · 2026-03-05
Leffler Eugene FrederickChief Financial Officer · Restricted Stock Units → Common StockDisposed 87 500exercise · 2026-03-05
Leffler Eugene FrederickChief Financial Officer · Restricted Stock Units → Common StockAcquired 62 500grant · 2026-03-04
Weber Kevin DanielDirector · Employee stock option (right to buy) → Common StockAcquired 20 000 @ $0,90grant · 2026-03-04
Hoffman Beth J.Director · Employee stock option (right to buy) → Common StockAcquired 20 000 @ $0,90grant · 2026-03-04
Lanckriet HeikkiDirector · Employee stock option (right to buy) → Common StockAcquired 20 000 @ $0,90grant · 2026-03-04
Leffler Eugene FrederickChief Financial Officer · Employee stock option (right to buy) → Common StockAcquired 62 500 @ $0,90grant · 2026-03-04
Luebbert HermannDirector, CEO & Chairman · Restricted Stock Units → Common StockAcquired 125 000grant · 2026-03-04
Luebbert HermannDirector, CEO & Chairman · Employee stock option (right to buy) → Common StockAcquired 125 000 @ $0,90grant · 2026-03-04
Jones George PatrickChief Commercial Officer · Employee stock option (right to buy) → Common StockAcquired 50 000 @ $0,90grant · 2026-03-04
Jones George PatrickChief Commercial Officer · Restricted Stock Units → Common StockAcquired 50 000grant · 2026-03-04
BORER JOHN J IIIDirector · Employee stock option (right to buy) → Common StockAcquired 20 000 @ $0,90grant · 2026-03-04
Biofrontera AGDirector, 10% owner · Series D Convertible Preferred Stock → Common StockAcquired 4 831 172 @ $0,00purchase · 2025-09-16
Jones George PatrickChief Commercial Officer · Employee stock option (right to buy) → Common StockAcquired 100 000 @ $1,00grant · 2025-09-15
Leffler Eugene FrederickChief Financial Officer · Restricted Stock Units → Common StockDisposed 87 500exercise · 2025-09-10
Luebbert HermannDirector, CEO & Chairman · Restricted Stock Units → Common StockDisposed 137 500exercise · 2025-09-10

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Biofrontera Inc Market data — financials · 2026-05-27
Biofrontera Inc Market data — analyst estimates · 2026-05-27

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

Leadership

Wilhelm K. T. ZoursChairman of the Supervisory Board

Insider activity

Mixed / flat0 buys · 0 sellsnet $02 insiders · last 365d

Leffler Eugene FrederickChief Financial Officer · Common StockOther 87 500 · 2026-03-05
Luebbert HermannDirector, CEO & Chairman · Common StockOther 137 500 · 2026-03-05
Leffler Eugene FrederickChief Financial Officer · Common StockOther 87 500 · 2025-09-10
Luebbert HermannDirector, CEO & Chairman · Common StockOther 137 500 · 2025-09-10

Short positioning

24.2Kshares short-13.4% vs prior

1days to cover

35.5%short of daily vol

20.5Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

BFRI.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Operating income (YoY) (2025-12-31 vs 2024-12-31): 34.1%Derived (calculated)
Net margin (FY 2025-12-31): -25.3%Derived (calculated)
Return on equity (FY 2025-12-31): -100.5%Derived (calculated)
Return on assets (FY 2025-12-31): -36.9%Derived (calculated)
Current ratio (FY 2025-12-31): 1.52xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 1.73xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -80.0%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 8.2%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 67.7%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 67.7%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 40.7%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -30.1%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 11.7%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 136.4%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 29.2%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 2.4%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 78.0%Derived (calculated)
Total operating expenses (annual): USD 53.05MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
Pre-tax income (annual): USD -10.51MSEC XBRL filing
Revenue (annual): USD 41.7MSEC XBRL filing
Total liabilities (annual): USD 18.08MSEC XBRL filing
Capex (annual): USD 2KSEC XBRL filing
Cash & equivalents (annual): USD 6.39MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated

2026-06-17FILING8-K filing →

2026-05-14FILING10-Q filing →

2026-05-14FILING8-K filing →

2026-04-30FILINGDEF 14A filing →

2026-03-19FILING10-K filing →

2026-03-19FILING8-K filing →

2026-03-09FILING8-K filing →

2026-03-05 00:00 UTCINSIDER14 insider transactions — 2026-03 12 derivative

2026-03-05INSIDERLeffler Eugene Frederick transacted 87.5k sh — Chief Financial Officer

2026-03-05INSIDERLuebbert Hermann transacted 137.5k sh — Director, CEO & Chairman

2026-03-05INSIDERLeffler Eugene Frederick disposed of 87.5k sh Restricted Stock Units — Chief Financial Officer

2026-03-05INSIDERLuebbert Hermann disposed of 137.5k sh Restricted Stock Units — Director, CEO & Chairman

2026-03-04INSIDERLanckriet Heikki acquired 20.0k sh Employee stock option (right to buy) — Director

2026-03-04INSIDERLeffler Eugene Frederick acquired 62.5k sh Employee stock option (right to buy) — Chief Financial Officer

2026-03-04INSIDERWeber Kevin Daniel acquired 20.0k sh Employee stock option (right to buy) — Director

2026-03-04INSIDERLuebbert Hermann acquired 125.0k sh Restricted Stock Units — Director, CEO & Chairman

2026-03-04INSIDERJones George Patrick acquired 50.0k sh Employee stock option (right to buy) — Chief Commercial Officer

2026-03-04INSIDERHoffman Beth J. acquired 20.0k sh Employee stock option (right to buy) — Director

2026-03-04INSIDERBORER JOHN J III acquired 20.0k sh Employee stock option (right to buy) — Director

2026-02-26FILING8-K filing →

2026-02-09FILING8-K filing →

2026-01-13FILING8-K filing →

2026-01-07FILING8-K filing →

2025-12-05FILINGS-1 filing →

2025-09-16 00:00 UTCINSIDER6 insider transactions — 2025-09 4 derivative

2025-09-16INSIDERBiofrontera AG acquired 3.0k sh Series D Convertible Preferred Stock — Director, 10% owner

2025-09-15INSIDERJones George Patrick acquired 100.0k sh Employee stock option (right to buy) — Chief Commercial Officer

2025-09-10INSIDERLeffler Eugene Frederick transacted 87.5k sh — Chief Financial Officer

2025-09-10INSIDERLuebbert Hermann transacted 137.5k sh — Director, CEO & Chairman

2025-09-10INSIDERLuebbert Hermann disposed of 137.5k sh Restricted Stock Units — Director, CEO & Chairman

2025-09-10INSIDERLeffler Eugene Frederick disposed of 87.5k sh Restricted Stock Units — Chief Financial Officer

2025-07-22 00:00 UTCINSIDER8 insider transactions — 2025-07 8 derivative

2024-07-12 00:00 UTCINSIDER1 insider transaction — 2024-07 1 derivative

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread